Clinical Trial Update: Intermediate-dose HAD Regimen for CEBPA Double-mutated AML [NA]

View source ↗

Summary

The document notes an ongoing clinical trial in China evaluating an intermediate-dose HAD regimen for CEBPA double-mutated acute myeloid leukemia, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML | NA | Status: RECRUITING